Zyvana M 2 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 1000 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The prolonged-release formulation ensures a sustained therapeutic effect, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Zyvana M 2 Forte is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal blood glucose levels. It should be used cautiously in patients with renal or hepatic impairment, and regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia is recommended. Contraindications include diabetic ketoacidosis, severe renal dysfunction, and conditions predisposing to hypoxia. This combination therapy offers a synergistic approach to glycemic management, targeting multiple pathophysiological defects in type 2 diabetes, thereby reducing the risk of microvascular and macrovascular complications associated with chronic hyperglycemia.